BioXcel's BXCL501 Data In Dementia Patients Reinforce Its Efficacy In Agitation
Company Plans Phase III Discussions In H1 2021
Execs said data from the institutional setting could be a bridge to other settings, while the duration of response indicates a real-world benefit that could aid adoption.
You may also be interested in...
The company is developing a sublingual thin film of dexmedetomidine that could be used to treat agitation in a wide range of indications after planned initial launches in schizophrenia and bipolar disorder.
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.
The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.